JP2019512493A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512493A5
JP2019512493A5 JP2018548192A JP2018548192A JP2019512493A5 JP 2019512493 A5 JP2019512493 A5 JP 2019512493A5 JP 2018548192 A JP2018548192 A JP 2018548192A JP 2018548192 A JP2018548192 A JP 2018548192A JP 2019512493 A5 JP2019512493 A5 JP 2019512493A5
Authority
JP
Japan
Prior art keywords
humanized antibody
human
composition
seq
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018548192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/022067 external-priority patent/WO2017160700A1/en
Publication of JP2019512493A publication Critical patent/JP2019512493A/ja
Publication of JP2019512493A5 publication Critical patent/JP2019512493A5/ja
Priority to JP2022092849A priority Critical patent/JP2022137024A/ja
Priority to JP2025065073A priority patent/JP2025118642A/ja
Withdrawn legal-status Critical Current

Links

JP2018548192A 2016-03-14 2017-03-13 移植片対宿主病の処置または予防の方法 Withdrawn JP2019512493A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022092849A JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US62/307,896 2016-03-14
US201662420825P 2016-11-11 2016-11-11
US62/420,825 2016-11-11
PCT/US2017/022067 WO2017160700A1 (en) 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022092849A Division JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法

Publications (2)

Publication Number Publication Date
JP2019512493A JP2019512493A (ja) 2019-05-16
JP2019512493A5 true JP2019512493A5 (cg-RX-API-DMAC7.html) 2020-05-14

Family

ID=58455657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018548192A Withdrawn JP2019512493A (ja) 2016-03-14 2017-03-13 移植片対宿主病の処置または予防の方法
JP2022092849A Pending JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A Pending JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022092849A Pending JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A Pending JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Country Status (12)

Country Link
US (1) US20190077868A1 (cg-RX-API-DMAC7.html)
EP (1) EP3430053A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019512493A (cg-RX-API-DMAC7.html)
KR (2) KR102667332B1 (cg-RX-API-DMAC7.html)
CN (2) CN109153721A (cg-RX-API-DMAC7.html)
AU (2) AU2017234010B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018068625A2 (cg-RX-API-DMAC7.html)
CA (1) CA3017758A1 (cg-RX-API-DMAC7.html)
IL (1) IL261767B1 (cg-RX-API-DMAC7.html)
MA (1) MA43755A (cg-RX-API-DMAC7.html)
MX (2) MX2018011025A (cg-RX-API-DMAC7.html)
WO (1) WO2017160700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
IL270201B2 (en) * 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
DK2637672T3 (en) * 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP7105188B2 (ja) * 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease

Similar Documents

Publication Publication Date Title
Couriel et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease
Taylor et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions
JP2025118642A (ja) 移植片対宿主病の処置または予防の方法
JP2019508448A5 (cg-RX-API-DMAC7.html)
Sgourakis et al. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review
Padiyar et al. Induction antibody therapy in kidney transplantation
Erdozain et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome
CA3127928A1 (en) Methods of treating multiple myeloma
US20250276061A1 (en) Method and composition for inducing tolerance
Flinn et al. Recent advances in graft-versus-host disease
JP2019508448A (ja) 移植片対宿主病予防の方法
Choi et al. Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients
JP2024001191A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
JP2024503432A (ja) 抗cd38抗体及び抗cd38抗体の使用
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
Warren et al. Modulating alloimmune responses with plasmapheresis and IVIG
Książek et al. Primary immune thrombocytopenia in children
CN1527840A (zh) Cd25结合分子在类固醇耐受型患者中的用途
EP1100829B1 (en) Use of basiliximab in the treatment of rheumatoid arthritis or skin diseases
Meijer et al. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody
US20230073248A1 (en) Compositions and methods for inducing immune tolerance in transplantation recipients
Russell et al. Allogeneic transplantation using peripheral blood stem cells
Dodd et al. Renal Transplant Rejection
Busca The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation
Devraj et al. Impact of Induction Therapy on Clinical Outcomes of Kidney Transplant Recipients: A Single-Centre Cohort Study